A B S T R A C T Our study describes a novel human erythrocyte protein antigen, the expression of which is regulated by the rare Lutheran inhibitor In(Lu) gene. We have produced a monoclonal antibody (A3D8) that bound strongly to erythrocytes from subjects with Lutheran phenotypes Lu(a+b+), Lu(a+b-), and Lu(a-b+) but bound negligibly to erythrocytes from subjects with the dominant form of Lu(a-b-) phenotype, reflecting inheritance of the In(Lu) gene. Importantly, erythrocytes from an individual with the recessive form of Lu(a-b-) phenotype (i.e., absence of the In(Lu) gene and absence of genes encoding for Lutheran antigens) showed reactivity with A3D8 antibody comparable to that seen with Lu(a+) or Lu(b+) erythrocytes. A3D8 antigen activity was also found on all leukocytes and in serum and plasma; this activity also appeared to be regulated by the In(Lu) gene in serum, plasma, and on a subset of leukocytes. Thus, we have identified a human erythrocyte protein whose expression is modified by the In(Lu) gene. This knowledge that such an antigen exists on erythrocytes and in normal plasma should allow further studies into the molecular genetics of the In(Lu) gene and into the functional and structural significance of the A3D8 antigen.
INTRODUCTION
Lutheran antigens were the first erythrocyte blood group system shown to be controlled by an independent dominant inhibitor gene (1) . This Lutheran inhibitory In(Lu)l gene is an autosomal gene, not linked to the Lutheran loci, which in the heterozygote, suppresses almost totally the expression of Lutheran antigens (2) (3) (4) (5) (6) (7) . Partial penetrance of the gene is also believed to account for some phenotypes with weak expression of Lutheran antigens, which is also inherited as a dominant trait (4, 8) . The In(Lu) gene is also known to reduce expression of other erythrocyte antigens, such as Auberger (Au'), Pi, and i (9, 10) . The mechanism for the action of the In(Lu) gene remains unknown; it has been postulated that it may turn off production of a precursor or backbone molecule required for expression of the Lu, Au', P1, and i antigens or that the In(Lu) gene may code for an enzyme that modifies the substrate of the Lu, Aua, Pi, and i gene products, thus reducing or preventing expression of these antigens (11) . Both Lua and Lub antigens have been shown to vary in strength from one family to another, such that a heterozygote for Lub in one family may express as much antigen as a homozygote in another family (4, 8, 12) . This phenomenon is also thought by some to reflect variants of the In(Lu) gene. Little progress has been made in understanding the action of the In(Lu) gene because both the gene product and its substrate(s) have remained unidentified. In this study, we report the identification via the use of murine monoclonal antibody (A3D8) of a novel erythrocyte cell surface protein whose expression is modified by the human In(Lu) gene. Knowles et al. (13) have recently reported two monoclonal antibodies that identify antigens, different from those described in this paper, also inhibited by the In(Lu) gene. Analysis and distribution of A3D8 antigen. Purified mononuclear cell suspensions were obtained from heparinized venous blood via Hypaque-Ficoll density centrifugation (17) . Peripheral blood T lymphocytes were isolated by formation of rosettes (ER) with neuraminidase-treated sheep erythrocytes, followed again by Hypaque-Ficoll density centrifugation (18) . Monocytes were identified by the presence of ingested latex particles after being incubated for 1 h at 37°C with latex particles. B lymphocytes were identified by the presence of surface Ig using fluorescein-labeled F(ab')2 goat anti-polyvalent human Ig (Cappel Laboratories, Cochranville, PA). Polymorphonuclear cells were purified using 3% dextran sedimentation followed by hypotonic lysis of erythrocytes (19 Blocking of A3D8 antibody binding to erythrocytes by whole serum or plasma. Group 0 erythrocytes were obtained from normal donors. A3D8 ascites fluid was diluted 1:10 in RPMI 1640 media supplemented with 2% BSA and 0.1% sodium azide. Aliquots of this stock solution were then further diluted to final concentrations of 1:1,000, 1:2,000, and 1:4,000 in either RPMI 1640 medium, serum, or plasma. The final concentrations of serum or plasma at these dilutions were 90, 95, and 97.5%, respectively. A nonerythrocytebinding hybridoma IgM antibody was similarly diluted as a control. Indirect fluorescent staining was then carried out as described above, and both the percentage of positive cells and their relative fluorescence intensity were analyzed by flow cytofluorography. It should be pointed out that this series of experiments utilized the incubation of serum or plasma with erythrocytes in the presence of antibody A3D8. In contrast, blocking of antibody A3D8 with various types of antisera (see previous section) utilized preincubation of erythrocytes with various alloantisera followed by several washes and then the addition of A3D8 antibody.
METHODS
Analysis of radioimmunoassay (RIA) and cytofluorographic data. RIA data were expressed as A counts per minute as determined by the equation: Acpm = cpm experimental -cpm control.
To compare cytofluorograph data from various experiments, samples were analyzed both for the percentage of fluorescent cells and for the channel of mean fluorescence i.e., the channel at which 50% of cells were brighter and 50% duller or negative.
Measurements of relative fluorescence were obtained by dividing the length of the three-phase log scale used by the cytofluorograph by 512 (the number of channels) to obtain a millimeter/channel measurement of 0.51 mm on standard 3 cycle semilogarithmic paper. The mean fluorescent channel for each sample was multiplied by 0.51 mm, and the resulting number measured along the log scale to obtain the mean relative fluorescence of the sample. Data were analyzed using the Student's t test.
RESULTS
Reduced expression of A3D8 antigen in the presence of the In(Lu) gene. A3D8 antigen was on the cell surface of all circulating lymphocytes, monocytes, polymorphonuclear leukocytes, and erythrocytes from all normal Lu(a+) or Lu(b+) donors tested. Regardless of ABO blood group or Rh phenotype, erythrocytes from a large panel of normal donors were all strongly positive when assayed for A3D8 antibody reactivity (Table I ). A3D8 antibody also reacted normally with cells with the following rare phenotypes: Bombay (Oh), [20] ) bound A3D8 antibody normally (Table I and Fig. 2 ). Erythrocytes negative for Au- berger and PI antigens-antigens known to be weakly expressed or absent on dominant Lu(a-b-) erythrocytes-also bound A3D8 antibody normally (Table I) A3D8 ascitic fluid up to a final concentration of 1:4,000.
The lymphocytes and monocytes of two unrelated dominant-type Lu(a-b-) donors, D.J. and M.C., were also tested for binding of A3D8 antibody. Both subjects had increased A3D8-populations of lymphocytes (56% of D.J. vs. 15% for the normal Lu(b+) control in one instance, 26% for M.C. vs. 13% for the normal Lu(b+) control in the other; Fig. 3 ). However, lymphocytes from both Lu(a-b-) donors that did react with A3D8 antibody did so with a distribution and relative fluorescence comparable to Lu(b+) subjects (Fig. 3C, D) . In contrast, monocytes from these dominant Lu(a-b-) donors showed a cytofluorographic pattern not seen using monocytes from 11 Lu(b+) donors. While monocytes from all 11 Lu(b+) subjects exhibited uniform strong reactivity with A3D8 antibody, monocytes from the Lu(a-b-) donors contained two populations-one, representing 40% of the monocytes, reacting with A3D8 very weakly, and a second population, also representing '40% of the monocytes, which bound A3D8 strongly (Fig. 3E, F) . Monocytes from the Lu(a-b-) donors also included a large population of A3D8-cells (15% of monocytes), while 95% of monocytes from all Lu(b+) subjects were strongly A3D8+ (Fig. 3E, F) . (21) .
Characterization of A3D8 antigen. A3D8 antigen showed marked sensitivity to trypsin digestion. Erythrocyte suspensions pretreated with 0.1 mg/ml trypsin showed decrease in A3D8 expression (Fig. 4) , and treatment of erythrocytes with 1 mg/ml of trypsin abolished all specific binding of A3D8 antibody. Identical results were obtained when peripheral blood lymphocytes were pretreated with trypsin before being stained with A3D8 antibody (Fig. 4) . In contrast, neuraminidase treatment of Lu(b+) erythrocytes or lymphocytes did not decrease A3D8 antibody binding.
Distribution of A3D8 antigen. A3D8 antigen was also present on cell types other than erythrocytes. Circulating B and T lymphocytes strongly bound antibody A3D8, as did monocytes and polymorphonuclear leukocytes. Antibody A3D8 also reacted strongly with many malignant lymphocyte cell lines, including HUT 78 and HUT 102 (Sezary T cell), HSB-2 (T-ALL) and the normal B cell lines SB, B958, and YT4E. However, all Burkitt's lymphoma B cell lines thus far tested (EB-3, Raji, and Daudi) did not bind A3D8. Circulating leukemic cells from patients with null ALL, T ALL, T and B CLL, prolymphocytic leukemia, and hairy cell leukemia have thus far all been positive for A3D8 (data not shown).
In addition, A3D8 antigen activity was found circulating in serum and plasma from Lu(b+) subjects. When group 0 Lu(b+) erythrocytes were incubated with nonsaturating amounts of A3D8 antibody in the presence of autologous or allogeneic serum or plasma, serum or plasma invariably produced inhibition of A3D8 binding (Fig. 5) . Normal serum or plasma from five Lu(a+) or Lu(b+) ABH secretor or nonsecretor donors produced inhibition of a nonsaturating dilution of A3D8 binding of 67±6% (mean±SEM). In contrast, the presence of plasma from two dominant-type Lu(a-b-) donors (DJ and MC) produced a mean inhibition of A3D8 binding to allogeneic Lu(b+) erythrocytes of only 33±9% (P < 0.05 compared to Lu(b+) plasma; Fig. 5 ). At lower dilutions of A3D8 ascites (1:8,000), both Lu(b+) and Lu(a-b-) plasma produced >90% inhibition of A3D8 binding (Fig. 5) . Serum Phylogenetic distribution of A3D8 antigen. A3D8 antibody bound to mononuclear cells and erythrocytes of higher primates, including gorillas, chimpanzees, orangutans, and Gibbon apes. A3D8 antibody did not bind, however, to the cells of all Old World Monkeys tested (Rhesus, pig-tail, stump-tail), and to the erythrocytes of other mammals, including sheep, cows, and rabbits. Two to four animals of each species were tested.
DISCUSSION
Our study describes a novel human erythrocyte cell surface antigen different from any other erythrocyte or leukocyte antigen previously identified with either alloantisera or monoclonal antibodies (13, (22) (23) (24) (25) (26) number of erythrocyte antigens including Lutheran, Auberger, i, and P1 (9, 10) . While the polysaccharide structures of the PI and i antigens are fairly well understood (11, 27) Lu6 . Other data that support this conclusion include strong expression of A3D8 antigen on cord blood erythrocytes, which express Lutheran antigens weakly, and our observation that Lu(a+b-), Lu(a-b+), and Lu(a+b+) cells bound A3D8 antibody equally well (Table I ). A3D8 antigen is also not identical to antigens identified by previously described monoclonal antibodies. Knowles and colleagues (13) (Fig. 3) . Similarly, normal cortical thymocytes from Lu(b+) subjects did not bind A3D8 antibody, whereas medullary thymocytes were strongly A3D8+. These data suggest that select tissues as well as discrete stages of differentiation within a particular cell type exist where the In(Lu) gene may not be expressed in dominant Lu(a-b-) subjects (i.e., lymphocytes and a subset of monocytes) and may be expressed in Lu(b+) subjects (i.e., cortical thymocytes). However, we cannot rule out the possibility that expression of A3D8 antigen is regulated in erythrocytes by the In(Lu) gene but in other tissues may be regulated by mechanisms unrelated to the In(Lu) gene.
Our finding of A3D8 antibody blocking activity in serum and plasma, and that the level of blocking activity is reduced in the presence of the In(Lu) gene, is of particular interest and may represent an entirely new observation in the area of soluble blood group antigens. To date, no Lutheran-related antigen nor In(Lu) gene controlled antigen (with the exception of i [29] ) has been found in plasma. Because there has been some controversy as to whether the secretor gene, which determines the presence of A, B, H, and Lewis substances in saliva, also affects their presence in serum (33, 34) , we tested both Lu(b+) non-secretors (se/se) and a dominant Lu(a-b-) secretor (M.C.). We found that the presence of plasma blocking activity of A3D8 antibody is not dependent on ABH secretor status, but is dependent on the absence of the In(Lu) gene 
